Flux, Michael C.
Smith, David G. http://orcid.org/0000-0001-7858-3785
Allen, John J. B.
Mehl, Matthias R.
Medrano, Andi
Begay, Tommy K.
Middlemist, Brandon H.
Marquart, Brandon M.
Cole, Steven P.
Sauder, Christina J.
Lowry, Christopher A. http://orcid.org/0000-0003-3920-5575
Raison, Charles L. http://orcid.org/0000-0001-6687-0066
Funding for this research was provided by:
Brain and Behavior Research Foundation
B. Braun-Stiftung
Institute of Mental Health Research provided funding; the Depressive and Bipolar Disorder Alternative Treatment Foundation also provided fundnig
Article History
Received: 18 March 2022
Revised: 16 March 2023
Accepted: 20 March 2023
First Online: 21 April 2023
Competing interests
: MCF serves as a consultant for Cybin. DGS reports no financial relationships with commercial interests. JJB reports no financial relationships with commercial interests. MRM reports no financial relationships with commercial interests. AM reports no financial relationships with commercial interests. TKB reports no financial relationships with commercial interests. BHM reports no financial relationships with commercial interests. BMM serves as an employee and shareholder of Mycobacterium Therapeutics Corporation. SPC reports no financial relationships with commercial interests. CAL serves on the Scientific Advisory Board of Immodulon Therapeutics, Ltd., is Cofounder and Chief Scientific Officer of Mycobacteria Therapeutics Corporation, serves as an unpaid scientific consultant to Aurum Switzerland AG, and is a member of the faculty of the Integrative Psychiatry Institute, Boulder, Colorado. CLR serves as a consultant to Usona Institute, Novartis, Biogen/Sage, and Emory Healthcare.